Compare FMNB & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | FMNB | FDMT |
|---|---|---|
| Founded | 1887 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 857.4M | 695.3M |
| IPO Year | 2010 | 2019 |
| Metric | FMNB | FDMT |
|---|---|---|
| Price | $16.35 | $11.52 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 7 |
| Target Price | $15.00 | ★ $31.71 |
| AVG Volume (30 Days) | 410.3K | ★ 577.3K |
| Earning Date | 04-22-2026 | 05-08-2026 |
| Dividend Yield | ★ 4.89% | N/A |
| EPS Growth | ★ 18.85 | 18.79 |
| EPS | ★ 0.76 | N/A |
| Revenue | ★ $279,922,000.00 | $85,209,000.00 |
| Revenue This Year | $52.63 | N/A |
| Revenue Next Year | $8.28 | $70.28 |
| P/E Ratio | $21.25 | ★ N/A |
| Revenue Growth | 3.89 | ★ 230194.60 |
| 52 Week Low | $12.23 | $5.97 |
| 52 Week High | $16.18 | $14.00 |
| Indicator | FMNB | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 72.34 | 58.16 |
| Support Level | $13.75 | $9.63 |
| Resistance Level | N/A | $11.89 |
| Average True Range (ATR) | 0.27 | 0.60 |
| MACD | 0.03 | 0.17 |
| Stochastic Oscillator | 99.62 | 81.58 |
Farmers National Banc Corp is a financial holding company based in the U.S. Along with its subsidiaries, it operates in the domestic banking, trust, retirement consulting, insurance, and financial management industries. The group offers a full range of commercial and retail banking services, including checking accounts, savings accounts, time deposit accounts, commercial, mortgage, and installment loans, safe deposit boxes, ATMs, internet banking, and other banking services. Additionally, it offers personal and corporate trust services in the areas of estate settlement, trust administration, employee benefit plans, and retirement services; insurance products, and other financial products and services. The group's reportable segments are Bank, which generates the maximum revenue, and Trust.
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).